Who is sponsoring NCT03303378?

NCT03303378 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT03303378?

Interventions in NCT03303378: melatonin (Helsinn Chemical Co, Biasca, Switzerland), Placebos.

What condition does NCT03303378 study?

NCT03303378 studies Reperfusion Injury, Myocardial.

Is NCT03303378 still recruiting?

NCT03303378 is currently status unknown. Last updated 6 October 2017.

Last reviewed 2017-10-06 · How we verify

NCT03303378

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Melatonin on Reperfusion Injury

Status unknown NA Last updated 6 October 2017

What this trial tests

NA trial testing melatonin (Helsinn Chemical Co, Biasca, Switzerland) in Reperfusion Injury, Myocardial in 190 participants. Status unknown.

Timeline

1 November 2017

Primary endpoint
1 November 2019

1 November 2019

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	190
Start date	1 November 2017
Primary completion	1 November 2019
Estimated completion	1 November 2019
Sites	1 location across China

Drugs / interventions tested

melatonin (Helsinn Chemical Co, Biasca, Switzerland) — full drug profile →
Placebos — full drug profile →

Conditions studied

Reperfusion Injury, Myocardial — all drugs for Reperfusion Injury, Myocardial →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 80, any sex, with Reperfusion Injury, Myocardial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute myocardial infarction is a major cause of mortality and morbidity. Primary percutaneous coronary intervention (pPCI) is currently the most effective treatment strategy in acute myocardial infarction. However, a sizable number of patients fail to restore optimal myocardial reperfusion, mostly because of the 'no-reflow' phenomenon. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Several studies have shown that melatonin protects against ischemia/reperfusion injury (IRI). In our previous study, melatonin markedly reduced infarcted area, improved cardiac function and reduced lactate dehydrogenase release in rats. The investigators planned to research the cardioprotective effects of intravenous melatonin administered prior to reperfusion and continued after restoration of coronary blood flow in patients with ST segment elevation myocardial infarction undergoing pPCI.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cardioprotective Melatonin: Translating from Proof-of-Concept Studies to Therapeutic Use.
Baltatu OC, Senar S, Campos LA, Cipolla-Neto J. · · 2019 · cited 32× · PMID 31491852 · DOI 10.3390/ijms20184342
The Therapeutic Strategies Targeting Mitochondrial Metabolism in Cardiovascular Disease.
Huang X, Zeng Z, Li S, Xie Y, et al · · 2022 · cited 14× · PMID 36559254 · DOI 10.3390/pharmaceutics14122760

Verify or expand the search:

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03303378 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 6 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03303378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing